Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Net Income towards Common Stockholders: 2015-2024

Historic Net Income towards Common Stockholders for Editas Medicine (EDIT) over the last 10 years, with Dec 2024 value amounting to -$237.1 million.

  • Editas Medicine's Net Income towards Common Stockholders rose 59.58% to -$25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.6 million, marking a year-over-year increase of 6.13%. This contributed to the annual value of -$237.1 million for FY2024, which is 56.38% down from last year.
  • Editas Medicine's Net Income towards Common Stockholders amounted to -$237.1 million in FY2024, which was down 56.38% from -$151.6 million recorded in FY2023.
  • Editas Medicine's Net Income towards Common Stockholders' 5-year high stood at -$116.0 million during FY2020, with a 5-year trough of -$237.1 million in FY2024.
  • Over the past 3 years, Editas Medicine's median Net Income towards Common Stockholders value was -$220.4 million (recorded in 2022), while the average stood at -$203.0 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 65.98% in 2021, then soared by 31.22% in 2023.
  • Editas Medicine's Net Income towards Common Stockholders (Yearly) stood at -$116.0 million in 2020, then tumbled by 65.98% to -$192.5 million in 2021, then declined by 14.51% to -$220.4 million in 2022, then surged by 31.22% to -$151.6 million in 2023, then crashed by 56.38% to -$237.1 million in 2024.